Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
A new study from Edith Cowan University (ECU) has shown that understanding the following motivations can help find personal goals and prevent dementia.
Read Full NewsPrograms offering telehealth counseling and nicotine replacement products should be part of routine oncology care, researchers say.
Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.
A new study explores whether germline profiling could refine the subclassification and prognosis of therapy-related myeloid neoplasms beyond treatment history alone.
1.
Reasons Behind Refusing Stem Cell Transplantation in Certain Myeloma Patients.
2.
Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study
3.
COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment
4.
A novel test shows promise for finding cervical adenocarcinoma, which is difficult to find.
5.
Lung nodules seen in a high percentage of non-smokers
1.
The Role of Alanine Aminotransferase in Liver Health and Disease
2.
Potential of Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer
3.
The Role of Calcium Corrections in Accurate Blood Test Results
4.
Undersanding Alemtuzumab: What You Need To Know About This Multiple Sclerosis Medication
5.
Uncovering the Subtle Signs of Leukemia: A Guide to Early Detection
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
2.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
4.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge